Pharmacotherapy for obsessive-compulsive disorder: Real-world evidence from a 10-year retrospective data analysis

Asian J Psychiatr. 2024 Jan:91:103847. doi: 10.1016/j.ajp.2023.103847. Epub 2023 Nov 24.

Abstract

We investigated pharmacotherapy trends for obsessive-compulsive disorder (OCD) patients at a Korean tertiary hospital from 2008 to 2017. Out of 1894 patients, 82.9% received at least one psychotropic medication, with prescription rates increasing over time. The most frequently prescribed drug classes were selective serotonin reuptake inhibitors (SSRIs, 80.5%), anxiolytics (57.5%), antipsychotics (47.2%), other antidepressants (21.1%), and mood stabilizers (18.4%). Combination therapy was administered to 79.7% of medicated patients, with SSRIs, anxiolytics, and antipsychotics being the most common combination. Comorbidities significantly increased the prescription rates of all psychotropic classes (P < 0.001). Our study offers insights that may aid in bridging the gap between OCD treatment guidelines and real-world clinical practice.

Keywords: Comorbidity; Obsessive-compulsive disorder; Pharmacotherapy; Real-world prescription patterns; Treatment guidelines.

MeSH terms

  • Anti-Anxiety Agents* / therapeutic use
  • Antipsychotic Agents* / therapeutic use
  • Humans
  • Obsessive-Compulsive Disorder* / drug therapy
  • Psychotropic Drugs / therapeutic use
  • Retrospective Studies
  • Selective Serotonin Reuptake Inhibitors / therapeutic use

Substances

  • Selective Serotonin Reuptake Inhibitors
  • Anti-Anxiety Agents
  • Psychotropic Drugs
  • Antipsychotic Agents